RGNT Trade Alert: How a European Expansion Announcement Sparked a Near-200% Move

On June 8th, 2026, Regentis Biomaterials (RGNT) released a significant operational update regarding its international expansion. The company officially announced that it will commence European surgeon training for GelrinC (its CE Mark-approved hydrogel implant for knee cartilage repair), beginning in the third quarter of 2026.

Regentis Biomaterials (RGNT) Strategic Partnerships: The hands-on training initiative is scheduled to launch at the Humanitas Research Hospital in Milan, Italy, with subsequent sessions mapped out across other core European markets.

Regentis noted in the release that its product addresses a massive global market, highlighting an estimated $3 billion market in the U.S. alone (roughly 470,000 annual cases) where no ready-to-use, off-the-shelf regenerative solution currently exists. Additionally, the stock’s broader catalyst timeline includes an ongoing pivotal U.S. Phase III FDA study that is over 50% enrolled.

With the news, RGNT began to appear in our bot scanner, we announced our call using our technical Analysis. The stock moved almost 200% in that day.